Results 111 to 120 of about 7,716 (188)

Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes. [PDF]

J Cent Nerv Syst Dis
Fang Y, Lu Y, Zhu S, Huang S.
europepmc   +1 more source

Aripiprazole- and Lurasidone-Induced Akathisia: A Case Report and Literature Review. [PDF]

Cureus
Kandra K.
europepmc   +1 more source

Initial lurasidone dosing in acute schizophrenia: Pragmatic and trajectory-aware clinical implications. [PDF]

World J Psychiatry
Liu Y, Liu T.
europepmc   +1 more source

Prevalence and associated factors of antipsychotic-induced extrapyramidal symptoms in the Tigray region. [PDF]

BMC Psychiatry
Gebremariam EH, Begashaw TD, Tsegay L, Kindeya GG, Weldemariam AG, Gebru WA, Kahsay HD, Tsegabrhan H.   +7 more
europepmc   +1 more source

Childhood-onset schizophrenia co-occurring with 3-hydroxyisobutyryl-CoA hydrolase deficiency: A rare dual diagnosis successfully treated with clozapine. [PDF]

Indian J Psychiatry
Garg N, Garg S, Dhyani M.
europepmc   +1 more source

Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs. [PDF]

ACS Pharmacol Transl Sci
Racz R, Kozell LB, Eshleman AJ, Bloom SH, Wolfrum KM, Schmachtenberg JL, Swanson TL, Ngai J, Schutzer WE, Janowsky A, Abbas AI, Stavitskaya L.   +11 more
europepmc   +1 more source

Substantia nigra-related gene polymorphisms associated with acute antipsychotic-induced movement disorders. [PDF]

Mil Med Res
Hashimoto K.
europepmc   +1 more source

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence. [PDF]

CNS Drugs
McIntyre RS, Kato M, Thase ME, Therrien F, Marrache AM, Ikehara K, Ardic F, Boucher M.   +7 more
europepmc   +1 more source